文献速递淋巴瘤

重新定义免疫球蛋白重链可变区突变比例临界值慢性淋巴细胞白血病患者的预后可能性

Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
PubMed 文献 · Br J Haematol · 2020-02-16

结论在独立队列及诊断时患者中验证,提示BL-CLL总体预后良好,但需排除亚组#2。

要点

  • 亚组#2在BL-CLL中富集(14% vs 2%),且TFT较短。
  • BL-CLL诊断时生物学特征与M-CLL相似,不利预后标志物频率低。

核心结论

  • BL-CLL预后良好,与M-CLL相似,但亚组#2病例除外。

主要发现

  • 队列1中BL-CLL(n=36,5%)的TFT与M-CLL(n=338)相似,显著长于UM-CLL(n=385)。
  • 亚组#2在BL-CLL中占14%(5/36),显著高于总体2%(15/759),且TFT较短。

关键数值与推荐

  • 亚组#2在BL-CLL中占14%(5/36),在总体中占2%(15/759)。

临床怎么用

  • BL-CLL患者总体预后良好,可按类似M-CLL管理,但需识别亚组#2病例,其TFT较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In chronic lymphocytic leukaemia (CLL), caution is warranted regarding the clinical implications of immunoglobulin variable heavy chain region (IGHV) rearrangements with a 'borderline' (BL) percentage of mutations (i.e. 97-97·9% IGHV identity). We analysed the IGHV mutational status in 759 untreated CLL patients (cohort 1). BL-CLL (n = 36, 5%) showed a time to first treatment (TFT) similar to that of M-CLL (n = 338) and significantly longer than that of UM-CLL (n = 385), despite the enrichment in subset #2 cases. In fact, CLLs belonging to subset #2 (n = 15/759, 2%) were significantly more frequent among BL-CLLs (n = 5/36, 14%), with a brief TFT. TFT of BL-CLL remained comparable to that of M-CLL also considering the 327 CLL patients evaluated at diagnosis. These findings were then validated in an independent cohort 2 of 759 newly diagnosed CLL patients (BL-CLL: n = 11, 1·4%) and in all newly diagnosed patients from cohorts 1 and 2 (n = 1 086, 84% stage A; BL-CLL: n = 47, 4·3%). BL-CLL at diagnosis showed a biological profile comparable to that of M-CLL with a low frequency of unfavourable prognostic markers, except for a significant enrichment in subset #2. Our data suggest that the prognosis of BL-CLL is good and similar to that of M-CLL, with the exception of subset #2 cases.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Raponi S, Ilari C, Della Starza I, et al. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. Br J Haematol. 2020. PMID: 32064595. doi:10.1111/bjh.16434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。